Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

PolyMedix completes public offering of units for aggregate gross proceeds of $20.7 million

PolyMedix Inc. (http://polymedix.com), an emerging biotechnology company developing acute care therapeutic drug products for infectious diseases and cardiovascular disorders, announced today that it has completed a public offering of units for aggregate gross proceeds of $20.7 million.

18 Nov 2009

Tel Aviv University develops new wound dressing packed with infection-fighting antibiotics

Despite advances in treatment regimens and the best efforts of nurses and doctors, about 70% of all people with severe burns die from related infections. But a revolutionary new wound dressing developed at Tel Aviv University could cut that number dramatically.

18 Nov 2009

Tips on how to prevent household members from getting sick during flu season

someone at home who has H1N1 (swine) flu, it is important for you to prevent other people in the house from getting sick, according to Gary Kalkut, MD, MPH, Senior Vice-President, Chief Medical Officer of Montefiore Medical Center.

18 Nov 2009

Entellus Medical completes its Series D financing totaling $30MM

Entellus Medical, the Minnesota-based developer of novel, less invasive treatments for chronic conditions of sinusitis, has completed its Series D financing totaling $30MM. The Series D round was led by new investor Essex Woodlands Health Ventures and supported by existing investors Split Rock Partners and SV Life Sciences.

17 Nov 2009

Recent developments at Burnham Institute for Medical Research

New antibiotics for methicillin-resistant Staphylococcus aureus (MRSA) and other pesky bacteria. Andrei Osterman and collaborators have used comparisons of bacterial genomes to identify new targets for antibiotics and produced first-generation chemical inhibitors of a class of bacterial enzymes, called NadDs (nicotinate mononucleotide adenylyltransferases).

17 Nov 2009

LEAD Therapeutics discovers orally available PARP inhibitor

LEAD Therapeutics, a privately held drug discovery company, today announced the discovery of a novel, orally available, PARP inhibitor with potent anti-tumor activity both as single-agent treatment and in combination with chemotherapy drugs.

17 Nov 2009

PPD, Janssen Pharmaceutica to develop therapeutic compounds for IBS and bacterial infections

PPD, Inc. today announced it has entered an agreement with Janssen Pharmaceutica N.V. to develop and commercialize two Phase II-ready therapeutic compounds, one to treat diarrhea-predominant irritable bowel syndrome (IBS-d) and the other to treat complicated skin and skin structure and respiratory infections.

17 Nov 2009

Sequella broadens the licensed therapeutic indications of its SQ109 lead drug candidate

Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing products to treat life-threatening infectious diseases, today announced that it amended an existing agreement with the National Institutes of Health (NIH) to significantly broaden the licensed therapeutic indications, or "field of use," for Sequella's lead drug candidate, SQ109.

16 Nov 2009

Aradigm commences patient dosage in Phase 2 trial of novel inhaled ciprofloxacin formulation

Aradigm Corporation today announced that the first patient was dosed in a 6-month, multicenter, international Phase 2 clinical trial of a novel version of inhaled ciprofloxacin (ARD-3150) in 40 adult patients with non-cystic fibrosis bronchiectasis.

16 Nov 2009

Hope for vaccine against Chlamydia

"Now that we know how the body defends itself against the Chlamydia bacteria, we can develop a vaccine that optimises that defence. We have a basic understanding of how the vaccine could work, but some work remains to be done. We believe that it will take a few years before the vaccine becomes a reality," says researcher Ellen Marks, the author of the thesis.

16 Nov 2009

Some combination drug therapies are counter-productive

Combination drug therapy has become a staple for treating many infections. For instance, doctors treat extensively drug resistant forms of tuberculosis with one drug that breaks down the pathogen's protective barriers and opens the door for another to deliver the deathblow.

16 Nov 2009

UIC receives federal grant to develop new antibiotics against anthrax, tularemia and plague

Researchers at the University of Illinois at Chicago have received a $4 million federal grant to develop new antibiotics to treat anthrax, tularemia and plague.

11 Nov 2009

Bayfront Medical Center to implement CareFocus clinical surveillance solution from Thomson Reuters

Bayfront Medical Center has selected Clinical Xpert CareFocus from Thomson Reuters as its clinical surveillance solution for improving Core Measures outcomes and patient safety indicator (PSI) scores while also supporting infection control and pharmacy intervention initiatives.

10 Nov 2009

Prolonged ED wait time is associated with poor clinical outcomes

One in four emergency department patients in 2006 waited longer to be evaluated by a clinician than recommended at triage, an increase from one in five in 1997, according to a report in the November 9 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

10 Nov 2009

Exposure to common infections may increase stroke risk

Cumulative exposure to five common infection-causing pathogens may be associated with an increased risk of stroke, according to a report posted online today that will appear in the January 2010 print issue of Archives of Neurology, one of the JAMA/Archives journals.

10 Nov 2009

New imagining technique may yield better antiviral and anti-cancer drugs

A recently devised method of imaging the chemical communication and warfare between microorganisms could lead to new antibiotics, antifungal, antiviral and anti-cancer drugs, said a Texas AgriLife Research scientist.

10 Nov 2009

Transatlantic task force to address antibiotic resistance established, experts welcome initiative

Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health worldwide.

7 Nov 2009

Experts applaud the EU Presidency for establishing a transatlantic task force to address antibiotic resistance

7 Nov 2009

Novexel commences comparative study of NXL103 to oral linezolid

Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today that its most advanced oral antibacterial NXL103 (flopristin/linopristin), has started a Phase II clinical trial in adults with acute bacterial skin and skin structure infections (ABSSSI). The trial is designed to assess the safety and efficacy of NXL103 in comparison to oral linezolid.

6 Nov 2009

Wide gap between perceived and real determinants of antibiotic prescription exists, says researcher

Antibiotic over-prescription is promoted by pediatricians' perception of parents' expectations. Research published in the open access journal BMC Pediatrics shows that pediatricians are more likely to inappropriately prescribe antibiotics for respiratory tract infections if they perceived parents were expecting a prescription.

6 Nov 2009

Antibiotic News and Research

Further Reading

PolyMedix completes public offering of units for aggregate gross proceeds of $20.7 million

Tel Aviv University develops new wound dressing packed with infection-fighting antibiotics

Tips on how to prevent household members from getting sick during flu season

Entellus Medical completes its Series D financing totaling $30MM

Recent developments at Burnham Institute for Medical Research

LEAD Therapeutics discovers orally available PARP inhibitor

PPD, Janssen Pharmaceutica to develop therapeutic compounds for IBS and bacterial infections

Sequella broadens the licensed therapeutic indications of its SQ109 lead drug candidate

Aradigm commences patient dosage in Phase 2 trial of novel inhaled ciprofloxacin formulation

Hope for vaccine against Chlamydia

Some combination drug therapies are counter-productive

UIC receives federal grant to develop new antibiotics against anthrax, tularemia and plague

Bayfront Medical Center to implement CareFocus clinical surveillance solution from Thomson Reuters

Prolonged ED wait time is associated with poor clinical outcomes

Exposure to common infections may increase stroke risk

New imagining technique may yield better antiviral and anti-cancer drugs

Transatlantic task force to address antibiotic resistance established, experts welcome initiative

Experts applaud the EU Presidency for establishing a transatlantic task force to address antibiotic resistance

Novexel commences comparative study of NXL103 to oral linezolid

Wide gap between perceived and real determinants of antibiotic prescription exists, says researcher

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News